The heparan sulfate proteoglycan syndecan-1 (Sdc1) modulates cell proliferation, adhesion, migration and angiogenesis. Proteinasemediated shedding converts Sdc1 from a membrane-bound coreceptor into a soluble effector capable of binding the same ligands. In breast carcinomas, Sdc1 overexpression correlates with poor prognosis and an aggressive phenotype. To distinguish between the roles of membrane-bound and shed forms of Sdc1 in breast cancer progression, human MCF-7 breast cancer cells were stably transfected with plasmids overexpressing wild-type (WT), constitutively shed and uncleavable forms of Sdc1. Overexpression of WT Sdc1 increased cell proliferation, whereas overexpression of constitutively shed Sdc1 decreased proliferation. Fibroblast growth factor-2-mediated mitogen-activated protein kinase signaling was reduced following small-interfering RNA (siRNA)-mediated knockdown of Sdc1 expression. Constitutively, membrane-bound Sdc1 inhibited invasiveness, whereas soluble Sdc1 promoted invasion of MCF-7 cells into matrigel matrices. The latter effect was reversed by the matrix metalloproteinase inhibitors N-isobutyl-N-(4-methoxyphenylsufonyl) glycyl hydroxamic acid and tissue inhibitor of metalloproteinase (TIMP)-1. Affymetrix microarray analysis identified TIMP-1, Furin and urokinase-type plasminogen activator receptor as genes differentially regulated in soluble Sdc1-overexpressing cells. Endogenous TIMP-1 expression was reduced in cells overexpressing soluble Sdc1 and increased in those overexpressing the constitutively membrane-bound Sdc1. Moreover, E-cadherin protein expression was downregulated in cells overexpressing soluble Sdc1. Our results suggest that the soluble and membrane-bound forms of Sdc1 play different roles at different stages of breast cancer progression. Proteolytic conversion of Sdc1 from a membranebound into a soluble molecule marks a switch from a proliferative to an invasive phenotype, with implications for breast cancer diagnostics and potential glycosaminoglycan-based therapies.
Introduction
The syndecans are a family of four highly conserved cell surface heparan sulfate (HS) proteoglycans, which are expressed in a celltype-and tissue-specific, developmentally regulated manner (1) (2) (3) . In the adult, syndecan-1 (Sdc1) is predominantly expressed by epithelial cells and leucocyte subpopulations. Moreover, its expression can be induced in a variety of cell types during development, wound repair and tumor progression (1, 3, 4) . The Sdc1 core protein contains highly conserved transmembrane and cytoplasmic domains, which mediate oligomerization and interact with the cytoskeleton (1, (5) (6) (7) . The extracellular domain harbors attachment sites for HS, as well as chondroitin sulfate chains (1, 3) , which are linear polymers of repetitive disaccharide units of uronic acids and variably sulfated N-acetylglucosamine (HS) or N-acetylgalactosamine (chondroitin sulfate), capable of forming specific ligand-binding motifs (1, 8) . The HS chains are considered the major functional extracellular domain of Sdc1, whereas few functions have been assigned to the extracellular protein moiety (9) (10) (11) . Ectodomain shedding reduces the number of surface receptors, thus downregulating signal transduction, converting membrane-bound Sdc1 into a soluble effector competing for the same ligands. Protein kinase C, protein tyrosine kinase and mitogen-activated protein kinase (MAPK) signal transduction pathways activate shedding, which is mediated by several metalloproteinases in a context-dependent manner (1, 10, 12) .
Sdc1 modulates numerous biological processes relevant to tumor progression. Sdc1 is a classical coreceptor for growth factors, angiogenic factors and chemokines (1, 3, 8) and acts as a cell and matrix adhesion receptor (1, 3) . In concert with integrins, Sdc1 influences cell spreading and motility (13, 14) and modulates protease activities and chemokine functions during inflammation and wound repair (2, 3, 15, 16 ). An engagement of Sdc1 in angiogenesis has been suggested in different mouse models and in clinical correlation studies (2, 3, (17) (18) (19) . Sdc1-deficient mice are resistant to induced breast cancer due to a cancer stem cell phenotype, further underlining its relevance for breast cancer progression (4, 8, 20) .
A prognostic value for Sdc1 expression was assigned in several cancer types, including breast cancer (8) . High Sdc1 expression has a predictive value for the response to neoadjuvant chemotherapy of primary breast cancer (21) . A study on 254 breast carcinoma cases correlated strong epithelial Sdc1 expression in 42% of the carcinomas with negative prognostic parameters (22) . A different study on 200 patients showed a significantly reduced 10 years of breast cancer-specific overall survival for patients displaying epithelial Sdc1 expression and estrogen receptor (ER)-negative status or stromal Sdc1 expression and ERpositive status (23) . In contrast, a study on 80 invasive ductal carcinoma patients indicated a loss of epithelial Sdc1 expression correlating with relapse-free survival (24) . These data strongly suggest important roles for Sdc1 in breast cancer progression; however, its exact function is still unknown, hampering efficient glycosaminoglycan-targeting therapies (8) . We hypothesized that some controversial clinical findings may be due to opposing functions of membrane-bound and shed Sdc1. Therefore, we studied the individual contributions of membrane-bound and soluble Sdc1 to breast cancer cell proliferation and invasiveness in vitro. Our findings confirm a differential role of both Sdc1 forms in the modulation of fibroblast growth factor (FGF)-2-mediated MAPK signaling, E-cadherin expression and protease activity.
Cell culture
The human breast cancer cell line MCF-7 was maintained in RPMI 1640 containing 10% FCS, 1% glutamine and 1% penicillin-streptomycin (19) in a humidified atmosphere of 5% CO 2 at 37°C. Sdc1 shedding was induced by treatment with 1 lM phorbol myristate acetate (PMA) (Calbiochem, La Jolla, CA) in serum-free medium for 15 min (10) .
Generation of stably transfected cell lines pcDNA3.1-based plasmids (Invitrogen, Karlsruhe, Germany) overexpressing a wild-type (WT), a constitutively membrane-bound (Sdc1-388UC) and a constitutively shed form (Sdc1-392CS) of murine Sdc1 have been described previously (10) . Stable MCF-7 cell transfection was performed using lipofectamine (Invitrogen) according to the manufacturer's instructions. After 48 h, cells were split and cultured in the presence of 1 mg/ml G418 to select for clones containing the plasmids. Neomycin-resistant clones were cultured in the presence of 800 lg/ml G418.
Cell proliferation assay Basal cell proliferation was evaluated using the indicator dye Alamar Blue (Biosource, Camarillo, CA). A total of 2.5 Â 10 3 cells per well were plated in triplicate in 96-well plates and cultured at 37°C for 48 h. Dye was added, and the colorimetric change was measured photometrically after 6 h according to the manufacturer's protocol. The median absorbance values of at least three independent experiments were used for statistical analysis.
Invasion assay and matrix metalloproteinase inhibitor treatments Twenty-five thousand cells in 0.5 ml RPMI/10% FCS were added in triplicates to the upper compartments of BioCoat Matrigel Invasion Chambers (BD Biosciences, Heidelberg, Germany). After 24 h, the medium was replaced by serum-free RPMI. To the lower compartment, 0.75 ml RPMI/20% FCS was added. After 48 h, the cells on the lower surface were fixed and stained with Diff-Quik dye (Medion, Duedingen, Switzerland). Excised and mounted filter membranes were photographed using a Zeiss Axiovert microscope equipped with Axiovision software (Zeiss, Jena, Germany) at Â100 magnification. For each membrane, cells in five visual fields were counted. Relative invasiveness was expressed as percentage of the cell number on compound-treated inserts compared with control inserts (n . 3). For matrix metalloproteinase (MMP) inhibitor studies, the following inhibitors were added to both compartments 24 h after cell plating: 3.5 nM tissue inhibitor of metalloproteinase (TIMP)-1 (Biomol, Hamburg, Germany), 10 nM TIMP-2 (Calbiochem), 1 lM (2R)-2-[(4-biphenylylsulfonyl)amino]-3-phenylpropionic acid (MMP-2/MMP9 inhibitor, Calbiochem), 1.5 and 15 lM N-isobutyl-N-(4-methoxyphenylsulfonyl) glycyl hydroxamic acid (Biomol).
Immunocytochemistry
Ten thousand cells per well were grown for 16 h in eight-well chamber slides (Nunc, Wiesbaden, Germany). For Sdc1/vinculin colocalization experiments, chamber slides were precoated with 10 lg/ml fibronectin (BD Biosciences). Cells were fixed with either ice-cold methanol (muSdc1/huSdc1) or 3.7% phosphate-buffered saline (PBS)-buffered formaldehyde (muSdc1/vinculin) and permeabilized with 0.1% Triton X-100 in PBS. Non-specific binding was blocked with PBS containing 1% Aurion BSA-c (DAKO, Glostrup, Denmark). Slides were subsequently incubated with rat-anti-mouse Sdc1 mAb 281-2 [BD Pharmingen, San Jose, CA, 1:1000 in PBS/1% bovine serum albumin (BSA)] and mouse-anti-human Sdc1 mAb (Serotec, Martinsried, Germany, 1:100) or mouse-anti-human vinculin mAb (Sigma, 1:250) overnight at 4°C. Primary antibody omission served as a negative control. Subsequently, samples were incubated for 1 h with ALEXA-Fluor-568-labeled goat-anti-rat IgG and ALEXA-Fluor-488 goat-anti-mouse IgG (both Invitrogen, 1:600 in PBS/1% BSA). Cell nuclei were visualized by 4#,6-diamidino-2-phenylindole staining. Slides were analyzed with a Leica DMLB fluorescence microscope equipped with a Leica DC300F camera (muSdc1/huSdc1) or with a Nikon PCM 2000 confocal microscope (muSdc1/vinculin) (Nikon, Düsseldorf, Germany). Images obtained using different fluorescence channels were merged using Adobe Photoshop 6.0 software.
Dot blot analysis
A total of 5 Â 10 5 transfected MCF-7 cells were seeded in six-well plates and cultured for 24 h in the presence of FCS. The medium was subsequently replaced by serum-free medium for 24 h. Cells were lysed in radioimmunoprecipitation buffer and protein content was determined by bicinchoninic acid assay (Pierce, Rockford, IL). Two hundred microliters of cleared (10 000g, 4°C, 10 min) cell culture supernatants were loaded on nitrocellulose membranes using a microfiltration apparatus (Bio-Rad, Hercules, CA). Membranes were blocked (15) and incubated for 16 h with the Sdc1 antibody 281-2 (1:100 in PBS/1% BSA) at 4°C. Immunoreactivity was visualized with a peroxidase-conjugated anti-rat-IgG antibody (Oncogene, Cambridge, MA, 1:1000) followed by an enhanced chemoluminescence reaction (SuperSignal, Pierce) and enhanced chemoluminescence-hyperfilm exposure (Amersham, Braunschweig, Germany). Digitalized images were analyzed densitometrically using ImageJ software (National Institutes of Health, Bethesda, MD), normalizing to protein content.
siRNA-treatment and western blot analysis siRNA knockdown was performed using an equimolar mixture of siRNAs #12527 and #12432 (Ambion, Cambridgeshire, UK) targeting the coding region of Sdc1 and a negative control siRNA (#301698, Qiagen, Hilden, Germany). MCF-7 cells were transfected with 40 nM siRNA using Dharmafect reagent (Dharmacon, Lafayette, CO) according to the manufacturer's instructions. Knockdown was confirmed by quantitative real-time polymerase chain reaction (PCR) and flow cytometry (see below). To analyze MAPK activation, Sdc1-silenced and control MCF-7 cells were serum starved for 48 h prior to stimulation ± 10 nM FGF-2 (R&D systems, Wiesbaden, Germany) for 10 min. Cell lysates were prepared using modified radioimmunoprecipitation buffer with proteinase inhibitors (25) . Thirty micrograms of protein per lane were separated on 12% gels and electrotransferred to Hybond nitrocellulose membranes (Amersham). Detection of phosphorylated p44/42-MAPK was performed using a rabbit polyclonal antibody (phospho-Thr202/Tyr204, Cell Signaling, Beverly, MA) diluted 1:1000 and horseradish peroxidase-conjugated anti-rabbit IgG (Cell Signaling, 1:2000). Subsequently, membranes were subjected to an enhanced chemoluminescence reaction and signal quantification with NIH ImageJ software, normalizing the densitometric values of phospho-MAPK to the total MAPK signal. For total MAPK detection, membranes were stripped with glycine buffer (pH 2.5), washed and reincubated with primary antibodies against p44/42-MAPK (Cell Signaling) followed by the procedure described above (25) . Urokinase-type plasminogen activator receptor (uPAR), furin, murine Sdc1 and human Sdc1 were detected analogously using rabbit-anti-uPAR (Santa Cruz Biotechnology, Santa Cruz, CA, 1:800), rabbit-anti-furin (Santa Cruz, 1:200), rat-anti-murine Sdc1 clone 281-2 (1:1000) and goat-anti-human Sdc1 (R&D systems, 1:1000) as primary antibodies.
Flow cytometry
Cells were harvested from culture flasks by incubation with 1.5 mM ethylenediaminetetraacetic acid in Ca/Mg-free PBS buffer for 10 min at 37°C with gentle agitation. Cells were washed in PBS and resuspended in cold buffer containing 1% FCS. A total of 2 Â 10 5 cells per sample were used for a single analysis. Following centrifugation, cells were resuspended in Hanks' balanced salt solution/2% BSA and incubated for 15 min at 25°C with titrated antibodies [phycoerythrin (PE) rat IgG2a, j-isotype control clone R35-95 'R-IgG-PE', 0.1 lg and PE rat-anti-mouse CD138 clone 281-2 'RAM CD138-PE', 0.1 lg (both BD Pharmingen); IOTest Anti-CD138-PC5 clone B-A38 'MAH-CD138-PC5', 3 ll and IOTest IgG1 (mouse) clone 679.1Mc7 'M-IgG-PC5', 3 ll (both Beckman Coulter, Fullerton, CA)]. The samples were analyzed using a Beckman Coulter FC500 flow cytometer. Murine Sdc1 expression was analyzed comparing the relative amount of mouse or human CD138-stained cells with the IgG-controls in transfected and non-transfected cells. Isotype-matched antibodies were used as negative controls and ,2% non-specific background staining was observed (c.f. supplementary Figure 2 , available at Carcinogenesis Online, for details).
TIMP-1 enzyme-linked immunosorbent assay
Fifty microliters of cell culture supernatant from the upper chamber of matrigel invasion assays was analyzed using the Quantikine human TIMP-1 immunoassay (R&D systems) as described by the manufacturer.
Quantitative real-time PCR Cellular RNA was isolated using the RNeasy kit (Qiagen) and transcribed into complementary DNA applying the Advantage RT-for-PCR-Kit (Clontech, Heidelberg, Germany). Quantitative PCR was performed using the Qiagen QuantiTect SYBR Green PCR kit in a LightCycler (Roche, Indianapolis, IN) as described previously (26) . Amplification specificity was verified using melting curve analysis and 2% agarose gel electrophoresis of the PCR products. Data were analyzed using the 2 ÀDDCt method after normalization to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Primer sequences are listed in Table I .
Microarray expression analysis
Total RNA was isolated from three biological replicates of Sdc1-392CS-transfected and control MCF-7 cells using the RNeasy kit (Qiagen). Preparation of biotin-labeled complementary RNA using the one-cycle labeling protocol, hybridization and scanning of the arrays was performed according to the manufacturer's instructions. A total of 3.6 lg of purified RNA and poly-A controls were used to generate complementary DNA, which was used to synthesize biotin-labeled complementary RNA. Fragmented complementary RNA was hybridized to Human Genome U133 Plus 2.0 arrays for 16 h at 60°C in a GeneChip Hybridization Oven 640 at 60 r.p.m. The arrays were washed and stained in a GeneChip Fluidics 450 station (Affymetrix, Santa Clara, CA),
followed by scanning using an Affymetrix GeneChip Scanner 3000. The raw data image was processed with GeneChip Operating Software v1.2 and analyzed using DNA-Chip Analyzer (27) . Cell intensity files were normalized to overall median intensity and expression values were calculated using a perfect match minus mismatch model. The Database for Annotation, Visualization and Integrated Discovery 2008 was used to verify the annotations of the filtered genes (n 5 396) and classify the genes into different ontology groups.
HS disaccharide analysis
Confluent cell monolayers were washed twice with ice-cold PBS, harvested by cell scraping, pelleted and washed before lyophilization. HS was isolated and digested essentially as described before by proteolytic digestion, nucleic acid removal and removal of chondroitin sulfate before digestion with heparin lyases (28) . Sample cleanup after chondroitinase digestion was achieved by passage over diethylaminoethyl anion exchange columns, eluted with 1 M NaCl and desalted before digestion with 50 mU chondroitinase ABC (Seikagaku, Tokyo, Japan) in 100 ll of 40 mM Tris-acetate, pH 8, before repeated cleanup on diethylaminoethyl columns. The samples were then digested with 0.4 mU each of heparin lyases I-III (IBEX, Montreal, Canada) in 100 ll of heparin lyase buffer (5 mM N-2-hydroxyethylpiperazine-N#-2-ethanesulfonic acid, pH 7, and 1 mM CaCl 2 ) and incubated for 16 h at 37°C. Heat-inactivated digests were loaded for analysis by reversed-phase ion-pair chromatography-high-performance liquid chromatography as described (28) .
Statistical analysis
Data were expressed as mean ± SEM or SD, as indicated. Statistical analysis was performed using the Sigma Stat 3.1 software (Systat Software, Point Richmond, CA). An unpaired t-test was used when groups passed the normality test, and a Mann-Whitney test was used when the standard deviations of two groups differed significantly. A two-sided P-value ,0.05 was considered statistically significant. All calculations were performed on the means of triplicate-sextuplet measurements of at least three independent experiments.
Results
Heterologous overexpression of constitutively shed and constitutively membrane-bound Sdc1 in MCF-7 breast cancer cells To evaluate a potential differential role of membrane-bound and soluble Sdc1 on breast cancer cell behavior, we employed a stable transfection approach in MCF-7 breast cancer cells. Expression construct Sdc1-392CS encodes only the extracellular domain of Sdc1, whereas construct Sdc1-388UC allows for overexpression of an uncleavable, constitutively membrane-bound form in which the juxtamembrane shedding site is replaced by CD4 sequences (10) . Endogenously expressed human and overexpressed murine Sdc1, which share 70% amino acid sequence identity in their extracellular and 96 and 100% homology in their cytoplasmic and transmembrane domains (29) , can be distinguished using species-specific reagents. Functional equivalence of murine and human Sdc1 was demonstrated in several studies (29, 30) . MCF-7 cells were stably transfected with a pcDNA3.1 control vector, a pcDNA3.1-based Sdc1-WT, Sdc1-392CS and Sdc1-388UC constructs. A series of control experiments were performed to demonstrate overexpression, proper location and glycosaminoglycan substitution of the Sdc1 constructs. A significant level of messenger RNA (mRNA) overexpression was demonstrated for the heterologous constructs by real-time PCR ( Figure 1A ). Soluble ectodomain overexpression resulted in a 60% decrease of endogenous Sdc1 expression, whereas overexpression of WT and constitutively membrane-bound Sdc1 did not affect endogenous Sdc1 levels ( Figure  1A ). Dot blot analysis revealed 5-fold increased murine Sdc1 levels in Sdc1-392CS compared with Sdc1-WT conditioned media ( Figure  1B) . Using immunofluorescence microscopy, the colocalization of n.a. n.a.
n.s., not significant (P ! 0.05); n.a., not applicable.
Role of Sdc1 in breast cancer progression (10) . Since the HS chains represent the major functional extracellular domain of Sdc1, we analyzed the transfectants for glycosaminoglycan substitution of heterologously expressed Sdc1 and for possible changes in HS structure. A disaccharide analysis of the transfected cells did not reveal major differences in HS composition, except for a reduced sulfation degree in Sdc1-392CS-overexpressing cells ( Figure 1D ). Western blotting analysis of cell extracts for the expression of murine and human Sdc1 confirmed glycosaminoglycan substitution of both human and murine Sdc1, as revealed by the presence of high-molecular weight (80-190 kDa) bands ( Figure 1E ).
Differential effect of soluble and membrane-bound Sdc1 on breast cancer cell proliferation Sdc1 acts as a membrane-bound coreceptor for FGF receptor-mediated signaling (31) . However, soluble Sdc1 ectodomains can competitively inhibit heparin-mediated FGF-2 mitogenicity (29, 32, 33) . To characterize the role of endogenous Sdc1 in MCF-7 cell proliferation, we studied its function in FGF-2-mediated MAPK signaling as a downstream readout of FGF receptor activity. siRNA knockdown resulted in an 80% downregulation of endogenous Sdc1 expression in MCF-7 cells 48 h after transfection, as confirmed by quantitative PCR and flow cytometry (Figure 2A and B) . FGF-2 stimulation of serumstarved MCF-7 cells induced p44/42 MAPK phosphorylation, which could be significantly reduced by Sdc1 siRNA knockdown ( Figure  2C ). Proliferation assays revealed significantly increased proliferation rates in MCF-7 cells overexpressing WT Sdc1 compared with vector controls ( Figure 2D ). In contrast, overexpression of soluble Sdc1 inhibited MCF-7 breast cancer cell proliferation ( Figure 2D ).
The soluble Sdc1 ectodomain promotes breast cancer cell invasiveness via a TIMP-1-dependent mechanism Sdc1 acts as a matrix receptor and as a modulator of cell motility and of the proteolytic environment, key elements of the metastatic process (1, 8, 11) . We therefore investigated if MCF-7 cell invasiveness was differentially affected by overexpression of the soluble ectodomains, constitutively membrane-bound or WT Sdc1 using matrigel invasion chamber assays. Overexpression of WT Sdc1 increased MCF-7 cell invasiveness by 50% compared with vector controls ( Figure 3A) .
Overexpression of the soluble Sdc1 ectodomain led to a 130% increase, whereas constitutively membrane-bound Sdc1 overexpression entailed a 40% decrease of invasiveness ( Figure 3A) . Since Sdc1 modulates the activity of a variety of proteases, with potentially opposing physiological effects of the soluble and membrane-bound form (2,30,34,35), we tested if MMP inhibitors would differentially reduce invasiveness. N-isobutyl-N-(4-methoxyphenylsulfonyl) glycyl hydroxamic acid, an MMP inhibitor with broad specificity (36) (37) (38) , inhibited MCF-7 Sdc1-392CS invasiveness by 50%; however, it did not influence invasiveness of the other transfectants. The physiological inhibitor TIMP-1 inhibited MCF-7 Sdc1-392CS invasion by 40% and MCF-7 Sdc1-388UC invasion by .50%, whereas TIMP-2 and an MMP2/MMP9 inhibitor had no effect ( Figure 3B-E) .
Affymetrix microarray analysis for differential gene expression in MCF-7 control cells and MCF-7 cells overexpressing soluble Sdc1
Since Sdc1 modulates both expression and function of many factors relevant to cancer cell invasion and metastasis (8), we performed an Affymetrix microarray analysis to screen for genes differentially expressed between low-invasive MCF-7 vector control and highly invasive MCF-7 Sdc1-392CS cells. Relative to controls, 59 genes were significantly upregulated and 330 genes downregulated in cells overexpressing soluble Sdc1 by at least a factor of two ( Figure 4A ; supplementary Tables I and II are available at Carcinogenesis Online). Differentially regulated genes were placed into categories based on their Gene Ontology annotations (39), and candidate groups of genes potentially involved in the observed phenotypic changes in MCF-7 392CS cells were subjected to further analysis ( Figure 4B ; supplementary Table III is available at Carcinogenesis Online). Microarray analysis revealed a significant downregulation of TIMP-1. Quantitative PCR confirmed significant downregulation of TIMP-1 mRNA and upregulation of uPAR in MCF-7 Sdc1-392CS cells, providing clues for a proinvasive mechanism induced by soluble Sdc1 (Table I) . Expression changes affecting members of the Rho family of small guanosine triphosphatases and of integrin alphaV and beta5 subunits indicated that changes in cell motility might have caused increased invasiveness in MCF-7 Sdc1-392CS cells. However, quantitative PCR analysis (Table  I ) and western blotting (results not shown) could not confirm differential expression of RhoB and b5-integrin and of additional proinvasive factors like the hepatocyte growth factor receptor cMet or heparanase (8, 19) . Moreover, confocal immunofluorescence microscopy indicated that all cell lines were capable of forming focal adhesions ( Figure 4C ; supplementary Figure 1 is available at Carcinogenesis Online).
Overexpression of the soluble Sdc1 ectodomain induces downregulation of TIMP-1 and E-cadherin and increased uPAR expression
We next aimed at confirming the results of Affymetrix screening and real-time PCR analysis at the protein level. Since TIMP-1 mRNA expression was downregulated in MCF-7 Sdc1-392CS cells, we determined TIMP-1 protein in cell culture supernatants of all four transfectant cell lines by enzyme-linked immunosorbent assay. TIMP-1 levels were significantly decreased in cells overexpressing soluble Sdc1, whereas increased TIMP-1 amounts were detected in the media of cells overexpressing constitutively membrane-bound Sdc1 ( Figure 5A) . While E-cadherin mRNA expression was not significantly altered in MCF-7-Sdc1-392CS cells (Table I) , western blot analysis revealed significant downregulation of E-cadherin protein expression compared with controls ( Figure 5B) . Expression of the uPAR in MCF-7 cells overexpressing soluble Sdc1 was significantly upregulated at both mRNA and protein levels ( Figure 5C ). In contrast, transcriptional downregulation of the proprotein convertase furin did not translate into changes in protein expression ( Figure 5D ).
Discussion
In this study, we employed an overexpression approach to delineate the role of membrane-bound and soluble forms of Sdc1 in breast cancer cell behavior. We confirmed the correct localization and functional properties of the overexpressed Sdc1 constructs. In addition, we observed an occasional perinuclear and/or nuclear staining for Sdc1. While the perinuclear staining may be indicative of high biosynthetic activity in the ER of the syndecan-overexpressing cell lines, the nuclear localization is conform with reports on a cotrafficking of syndecans with nuclear FGF-2 in injured neurons (40) and on tubulin-mediated nuclear translocation of Sdc1 (41) . Although speculative, nuclear trafficking of Sdc1 may exert an influence on cellcycle progression or on FGF2-mediated transcriptional regulation.
We demonstrated extensive glycosaminoglycan substitution of the heterologously expressed Sdc1 constructs ( Figure 1E ), which is a prerequisite for their HS-dependent functions, as a multitude of ligands functionally interact with Sdc1 via its HS chains (1, 3) . Disaccharide analysis revealed the presence of very similar HS structures in the different MCF-7 transfectants. A slightly reduced overall sulfation was noted in MCF-7 Sdc1 392CS cells, yet unchanged levels of trisulfated disacharides. Reduced 6-O-sulfation can influence growth factor binding by HS (42) , as recently shown for the MCF-7-derived HS-editing enzyme HSulf-2 (43) . Therefore, we cannot fully exclude a partial contribution of reduced HS sulfation to the phenotype of MCF-7 Sdc1 392CS cells. The presence of unchanged amounts of trisulfated disaccharides together with the notion that much more HS was produced in these cells (data not shown) may suggest a high ligand-binding capacity also in these cells.
Our coimmunolocalization data suggest that in cells overexpressing the uncleavable Sdc1 mutant, endogenous Sdc1 may also become resistant to shedding, possibly due to heterodimer formation (5,10). A cell rounding upon soluble Sdc1 ectdomain overexpression ( Figure  1C panel Sdc1 392CS) has previously been attributed to b1-integrin activation (44); however, focal adhesion formation was not impaired ( Figure 4C ; supplementary Figure 1 is available at Carcinogenesis Online). Moreover, no significantly different alphaV-and b5-integrin expression was observed, consistent with reports on the lack of an inhibitory effect of Sdc1 on aVb1-integrin-dependent spreading and of Sdc1 inhibiton on MCF-7 migration through vitronectin-and fibronectin-coated filters (13) .
Sdc1 siRNA knockdown caused significantly decreased FGF-2-induced MAPK activation (Figure 2 ), in accordance with its coreceptor role for FGF-2 signaling (1,31) . In MCF-7 cells, Sdc1 and -4 contribute to the formation of a ternary complex of FGF-2, FGFR-1 and the syndecans' HS chains (45) . In line with the inhibitory effect of Sdc1 knockdown on mitogenic signaling, overexpression of WT Sdc1 increased the number of coreceptors at the cell surface, resulting in increased cell proliferation rates (Figure 2 ). In contrast, soluble ectodomain overexpression significantly inhibited MCF-7 proliferation (Figure 2 ). Soluble Sdc1 inhibits both heparin-binding epidermal growth factor-like growth factor and heparin-mediated FGF-2 mitogenicity (1, 32) , and exogenously added Sdc1 ectodomains inhibit MCF-7 cell proliferation (28) . In turn, FGF-2 induces Sdc1 shedding, providing a mechanism for coreceptor desensitization (30) . Decreased TIMP-1 expression ( Figure 5 ) may have additionally reduced MCF-7 Sdc1-392CS cell proliferation since TIMP-1 stimulates MCF-7 cell proliferation via MAPK activation (46, 47) .
Our study demonstrated that overexpression of WT Sdc1 and its soluble ectodomain significantly promote, whereas the constitutively membrane-bound form inhibits invasiveness of MCF-7 cells (Figure 3) . Microarray analysis revealed differential expression of genes involved in proteolytic processes (TIMP-1, uPAR and furin) between highly invasive MCF-7 Sdc1-392CS and control cells. Membrane-bound and soluble Sdc1 differentially modulate proteolytic processes in various experimental systems by targeting different proteins such as elastases, MMP-7, MMP-17 a disintegrin and metalloproteinase with thrombospondin-like motifs-4 and proprotein convertase PC5A (2, 15, 30, 35, 48) . Our data point to a role for differential TIMP-1 expression as a relevant proinvasive factor in MCF-7 Sdc1-392CS cells and an anti-invasive factor in MCF-7 Sdc1-388UC cells since TIMP-1 secretion was either downregulated or upregulated in these cells. Moreover, addition of TIMP-1 to the culture medium of MCF-7 Sdc1-392CS cells significantly inhibited the increased invasiveness. The preferential inhibitory effect of N-isobutyl-N-(4-methoxyphenylsulfonyl) glycyl hydroxamic acid may indicate an important role of a disintegrin and metalloproteinases (ADAMs) in this process, conform with the role of ADAM10 in E-cadherin shedding (49) and the observed downregulation of E-cadherin levels ( Figure 5A ). TIMP-1 inhibits the proteolytic activity of (non-MT-) MMPs and some ADAMs (ADAM10 and a disintegrin and metalloproteinase with thrombospondin-like motifs) via non-covalent binding to both active and pro-forms of these enzymes (47, 50, 51) . Surprisingly, TIMP-1 did not reduce invasiveness of MCF-7 Sdc1-WT cells. This finding suggests a regulatory function of the equilibrium between membranebound and soluble forms of Sdc1. The observed Sdc1-induced changes in TIMP-1 expression and susceptibility are probably based on alterated signaling processes, as suggested by the effect of Sdc1 siRNA knockdown on MAPK signaling ( Figure 2C) , and by the differential regulation of several members of the MAPK family (MAP3K8 and MAP2K), and upstream signaling molecules (EGF receptor ERBB2, epidermal growth factor receptor pathway substrate 15-like 1 and integrin-linked kinase) observed in the Affymetrix screening (supplementary Tables I and II are available at Carcinogenesis Online). In turn, TIMP-1 modulates MAPK signaling in MCF-7 cells (46, 47) . We can currently only speculate that overexpression of either the soluble or membrane-bound form of Sdc1 leads to an activation of pathways modulating TIMP-1 expression and susceptibility, whereas these parameters remain stable if the homeostasis between the two Sdc1 forms is intact. Upregulation of the prognostic factor uPAR (52) in MCF-7 Sdc1-392CS cells was identified as an additional element contributing to increased invasiveness ( Figure 5 ). uPA binds to its receptor uPAR, thereby enhancing its ability to activate plasmin (52) . This provides a potent protease capable of degrading most components of extracellular matrix. Like Sdc1, uPAR indirectly regulates cell adhesion and motility via modulation of avb3 integrin function (13) . PMA-induced uPAR upregulation in MCF-7 cells causes increased plasminogen binding and activation (53) , concomitant with increased Sdc1 shedding ( Figure 1C panel Sdc1 388UC). Anti-uPAR antibodies suppress tumor growth and metastasis in MCF-7 xenograft models (52) . Furthermore, stromal derived factor (SDF)-1/CXC chemokine receptor 4-mediated upregulation of uPAR in breast cancer cells promotes Finally, downregulation of E-cadherin protein expression was identified as a contributing factor to increased invasiveness of MCF-7 Sdc1-392CS cells ( Figure 5) . Reduced E-cadherin expression in Role of Sdc1 in breast cancer progression breast cancer is associated with lymph node metastasis and reduced disease-free survival (55, 56) . Sdc1 and E-cadherin are co-ordinately regulated [c.f. (19) for discussion] and coimmunoprecipitate with the transcriptional regulator b-catenin, suggesting functional and physical association (6) . Since E-cadherin, like Sdc1, is required for maintaining the epitheloid phenotype (1, 55) , its downregulation in soluble Sdc1-overexpressing cells facilitates loosening of cell-cell contacts, thus promoting invasiveness. Affymetrix data on the downregulation of 33 genes involved in cell adhesion support this mechanistic concept ( Figure 4B ).
In summary, we have demonstrated opposing roles for membranebound and soluble forms of Sdc1 in human MCF-7 breast cancer cells. In MCF-7 cells, WT Sdc1 promoted cell proliferation as a coreceptor of mitogenic MAPK signaling, whereas its soluble form inhibited proliferation. In contrast, the constitutively membranebound form inhibited in vitro invasiveness, whereas soluble Sdc1 vastly promoted MCF-7 invasion. Among the multitude of established human breast cancer cell lines, MCF-7 cells represent the more benign spectrum (57) . Therefore, the observed Sdc1-induced phenotype may not be representative for all breast cancer cells and may be modulated by the cell-type-specific expression signature of additional receptors, adhesion molecules, growth factors and proteases (19) . Microarray analysis revealed that overexpression of soluble Sdc1 was associated with complex changes in the expression pattern of nearly 400 gene products, among which the modulation of proteolytic activity and signal transduction pathways emerged as important motifs relevant to the observed phenotypic changes ( Figure 3 , Table I; supplementary Tables I-III are available at Carcinogenesis Online). Although dysregulation of RhoB was not confirmed in an independent data set (Table I) , the large number of differentially regulated Rho-family guanosine triphosphatases (RhoB, RhoC, RhoD and Cdc42) of associated regulatory proteins (Rho-related BTB domain 3, Rho guanine nucleotide exchange factor and SLIT-ROBO Rho GTPase activating protein) and of cytoskeletal elements (smoothelin, alpha actinin and transgelin) identified by Affymetrix screening is highly suggestive of a mechanistic contribution of soluble Sdc1 to the modulation of cell motility as part of the invasion phenotype (supplementary Tables I-III are  available at Carcinogenesis Online). This view is supported by an increasing number of reports on the interplay of syndecans and Rhofamily guanosine triphosphatases (reviewed in ref. 14) and warrants future investigation. We confirmed a coreceptor role for Sdc1 in MAPK-mediated signaling in breast cancer cells and a role for soluble Sdc1 in the regulation of TIMP-1, uPAR and E-cadherin expression, resulting in synergistic promotion of breast cancer cell invasiveness. We propose that TIMP-1-sensitive protease-mediated shedding of Sdc1, mimicked by the Sdc1-392CS expression construct, represents a switch from a proliferative to an invasive phenotype in MCF-7 cells. This model is able to explain seemingly contradictory results on the prognostic role of Sdc1 in breast cancer (18, (22) (23) (24) . In histopathological analyses, soluble Sdc1 may have been lost during sample preparation. Therefore, specimens regarded as Sdc1 negative due to low membranous epithelial staining may in fact represent a tumor subtype with a high potential to metastasize. Our findings also have a therapeutic perspective, considering that the major functional domains of soluble Sdc1 are its heparin-related HS chains. In early stages of tumor progression, competitive glycosaminoglycan-based approaches targeting the interaction of growth factors with Sdc1 emerge as a promising anti-proliferative strategy. In contrast, some glycosaminoglycans may potentially mimic the soluble Sdc1 ectodomain and may promote rather than inhibit metastasis at later stages of cancer progression. Heparanase induces Sdc1 expression and shedding, which promotes tumor invasion (58) . Therefore, the combined use of Sdc1 shedding inhibitors, MMP inhibitors and heparanase-inhibiting heparinoids may be a promising anti-metastatic approach at late stages of breast cancer progression (8, 59) . The results of our study therefore underline the importance of a mechanistic understanding of the biological roles of prognostic markers for the development of targeted therapeutic approaches.
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